Alvotech Acquires Ivers-Lee to Boost Biosimilar Packaging Capacity

Alvotech ( (ALVO) ) just unveiled an update.

On July 9, 2025, Alvotech announced its acquisition of Ivers-Lee Group, a Swiss company specializing in pharmaceutical assembly and packaging services. This acquisition is set to enhance Alvotech’s capacity and flexibility in meeting the growing global demand for biosimilars, supporting its plans to launch three new biosimilars in 2025. The integration of Ivers-Lee into Alvotech’s operations is expected to provide stability and growth opportunities for both companies, while maintaining high-quality service for existing clients.

The most recent analyst rating on (ALVO) stock is a Hold with a $14.00 price target. To see the full list of analyst forecasts on Alvotech stock, see the ALVO Stock Forecast page.

Spark’s Take on ALVO Stock

According to Spark, TipRanks’ AI Analyst, ALVO is a Neutral.

Alvotech’s score is primarily influenced by its financial performance, which indicates rapid growth but significant financial instability. The earnings call provided a positive outlook with raised guidance and strategic product launches. However, technical analysis shows bearish signals and valuation is moderately high, affecting the overall score.

To see Spark’s full report on ALVO stock, click here.

More about Alvotech

Alvotech is a global biotech company focused on the development and manufacture of biosimilar medicines for patients worldwide. The company aims to be a leader in the biosimilar space by delivering high-quality, cost-effective products and services. Alvotech has a robust pipeline of biosimilar candidates targeting various diseases and has formed strategic commercial partnerships to expand its global reach.

Average Trading Volume: 202,924

Technical Sentiment Signal: Sell

Current Market Cap: $2.72B

Learn more about ALVO stock on TipRanks’ Stock Analysis page.